Fate Therapeutics gets $15 million CIRM grant for lupus nephritis CAR T trial
The state stem cell agency's CLIN2 award backs Fate's Phase 2 RECLAIM-LN study of off-the-shelf CAR T therapy FT819 in refractory lupus nephritis.
SEC filing
Latest
3 stories
Monday, September 28
Wednesday, September 2
Fate Therapeutics registers Phase 1/2 trial of FT839 across five autoimmune diseases
Thursday, August 13
Fate Therapeutics doses first lupus nephritis patient in Phase 2 FT819 trial, clears FT839 IND
The company reported second-quarter 2026 results alongside pipeline updates across three CAR T-cell candidates and cash runway extending into 2028.
SEC filing